ArticleInvestigational new drugs2014

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Ajay K Gopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.